Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
September 18, 2024 08:54 ET
|
G1 Therapeutics
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
September 05, 2024 06:30 ET
|
G1 Therapeutics
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024 06:30 ET
|
G1 Therapeutics
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
Pharmacosmos Group to Acquire G1 Therapeutics
August 07, 2024 06:29 ET
|
G1 Therapeutics; Pharmacosmos
Pharmacosmos Group to Acquire G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024 18:50 ET
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024 11:15 ET
|
G1 Therapeutics
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business
Update on August 8, 2024
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
July 01, 2024 08:00 ET
|
G1 Therapeutics
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
June 24, 2024 06:30 ET
|
G1 Therapeutics
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024 07:00 ET
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024 06:30 ET
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC